Cmp Dev Llc Company Profile

What is the competitive landscape for CMP DEV LLC

CMP DEV LLC has six approved drugs.

There are thirty US patents protecting CMP DEV LLC drugs.

There are sixteen patent family members on CMP DEV LLC drugs in nine countries and sixty-six supplementary protection certificates in fourteen countries.

Summary for Cmp Dev Llc

International Patents:	16
US Patents:	30
Tradenames:	6
Ingredients:	6
NDAs:	6

Drugs and US Patents for Cmp Dev Llc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cmp Dev Llc	NORLIQVA	amlodipine besylate	SOLUTION;ORAL	214439-001	Feb 24, 2022		RX	Yes	Yes	12,226,528		Y
Cmp Dev Llc	TADLIQ	tadalafil	SUSPENSION;ORAL	214522-001	Jun 17, 2022		RX	Yes	Yes	11,975,006		Y
Cmp Dev Llc	LIQREV	sildenafil citrate	SUSPENSION;ORAL	214952-001	Apr 28, 2023		DISCN	Yes	No	11,759,468		Y
Cmp Dev Llc	NORLIQVA	amlodipine besylate	SOLUTION;ORAL	214439-001	Feb 24, 2022		RX	Yes	Yes	12,005,141		Y
Cmp Dev Llc	TADLIQ	tadalafil	SUSPENSION;ORAL	214522-001	Jun 17, 2022		RX	Yes	Yes	11,382,917		Y
Cmp Dev Llc	NORLIQVA	amlodipine besylate	SOLUTION;ORAL	214439-001	Feb 24, 2022		RX	Yes	Yes	11,723,866		Y
Cmp Dev Llc	NORLIQVA	amlodipine besylate	SOLUTION;ORAL	214439-001	Feb 24, 2022		RX	Yes	Yes	11,458,095		Y

International Patents for Cmp Dev Llc Drugs

Country	Patent Number	Estimated Expiration
European Patent Office	3368045
European Patent Office	3731870
Canada	3003028
World Intellectual Property Organization (WIPO)	2017212409
World Intellectual Property Organization (WIPO)	2017075463
European Patent Office	3731870
China	111683683

Supplementary Protection Certificates for Cmp Dev Llc Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2059246	LUC00371	Luxembourg		PRODUCT NAME: A COMBINATION OF (A) MACITENTAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND (B) TADALAFIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/24/1859 20240930
0247633	97C0118	France		PRODUCT NAME: ATORVASTATINE CALCIQUE TRIHYDRATE; REGISTRATION NO/DATE IN FRANCE: NL 21960 DU 19970321; REGISTRATION NO/DATE AT EEC: PL 00018/0240 DU 19961107
2059246	2024C/552	Belgium		PRODUCT NAME: EEN COMBINATIE VAN (A) MACITENTAN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT HIERVAN EN (B) TADALAFIL OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: EU/1/24/1859 20240930
2101777	300813	Netherlands		PRODUCT NAME: AMBRISENTAN TOEGEPAST IN COMBINATIEBEHANDELING MET TADALAFIL; REGISTRATION NO/DATE: EU/1/08/451 (C(2008) 1637) 20151125
1718641	SPC/GB12/028	United Kingdom		PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209
0503785	C300486	Netherlands		PRODUCT NAME: COMBINATIE VAN OLMESARTANMEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, AMLODIPINEBESYLAAT AND HYDROCHLOORTHIAZIDE; NATL REGISTRATION NO/DATE: RVG 106667, RVG 106671-74, RVG 106682-86 20101221; FIRST REGISTRATION: DE 79810.00.00-79814.00.00 20101216
1441735	08C0026	France		PRODUCT NAME: RALTEGRAVIR POTASSIUM; REGISTRATION NO/DATE: EU/1/07/436/001 20080102

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Cmp Dev Llc
• Cmp Pharma Inc

Last updated: July 29, 2026

CMP DEV LLC Competitive Landscape Analysis: Market Position, Strengths & Strategic Insights

CMP DEV LLC’s competitive posture in branded and generic pharmaceutical development is defined by where its programs sit in the value chain: early R&D and CMC execution versus late-stage clinical/regulatory execution and monetization through licensing, settlements, or ANDA launches. The firm’s market impact is best evaluated by mapping (1) its pipeline stage and therapeutic focus, (2) whether it plays offense through Para IV filings or defense through exclusivity-protected commercialization, and (3) how its manufacturing and regulatory credibility affects customer or partner allocation decisions.

No complete, source-backed dataset is available in the prompt to identify CMP DEV LLC’s specific drug targets, portfolio companies, FDA submissions, Orange Book listings, Para IV litigation, settlements, registered facilities, or revenue/contract references. Under the operating constraints, producing an accurate competitive landscape with patent-expiration dates, litigation status, or product-level launch risk is not possible.

CMP DEV LLC market position

Featured snippet answer: Without verified program and regulatory identifiers, CMP DEV LLC’s market position cannot be quantified against specific competing drugs, competitors, or geographic commercialization.

What strengths does CMP DEV LLC bring to pharmaceutical development?

Featured snippet answer: Strengths depend on the firm’s actual portfolio execution (CMC performance, filing throughput, regulatory outcomes, and enforcement outcomes). No portfolio specifics are provided in the input.

Which competitive threats does CMP DEV LLC face in pharma?

Featured snippet answer: Competitive threats are typically defined by (1) faster generic challengers, (2) stronger CMC-ready competitors for difficult formulations, (3) patent estate durability of originators, and (4) customer preference for sponsors with established FDA track records. These require program-level mapping that is not present.

How does CMP DEV LLC compare with peers by stage and therapeutic focus?

Featured snippet answer: Stage and therapeutic focus comparisons require known pipeline candidates, indicated uses, dosage forms, and regulatory pathway details.

Which partnerships matter most to CMP DEV LLC’s growth strategy?

Featured snippet answer: Partnership strength is measurable only through documented collaboration agreements, sponsored filings, co-development sponsors, or license/supply agreements tied to specific assets.

---

Key Takeaways

• CMP DEV LLC’s competitive landscape cannot be rendered with required patent, regulatory, litigation, or market-position specificity from the provided prompt.
• A business-grade competitive analysis requires program-level identifiers (assets, sponsors, FDA submissions, and patent listings). Those are not supplied.

---

FAQs

1. How do Para IV filing strategies typically change a developer’s competitive position?
2. What metrics best compare CMC capability across generic developers?
3. How should investors evaluate a sponsor’s likelihood of successful ANDA approval?
4. What drives customer selection for co-development or licensing partnerships in pharma?
5. How do patent estate strength and formulation complexity affect generic launch timing?

---

References

No sources were provided or extractable from the prompt.